GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...
NEW YORK CITY, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.
9h
GlobalData on MSNGSK’s Penmenvy meningococcal vaccine gains FDA approvalThe studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...
Over the past year, the GSK (LSE: GSK) share price has lagged behind the FTSE 100, falling 14% versus the Footsie’s gain of ...
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The ...
Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
GSK Pharma delivered a better-than-expected performance in Q3, largely driven by robust volume growth in the general medicine ...
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against five meningococcal serogroups, the company announced.The vaccine, branded as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results